| " PULSATILE" HIGH-DOSE WEEKLY ERLOTINIB FOR CENTRAL NERVOUS SYSTEM (CNS) METASTASES FROM EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) C Grommes, GR Oxnard, MG Kris, VA Miller, W Pao, AB Lassman NEURO-ONCOLOGY 12, 55-56, 2010 | | 2010 |
| “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer C Grommes, GR Oxnard, MG Kris, VA Miller, W Pao, AI Holodny, ... Neuro-oncology 13 (12), 1364-1369, 2011 | 373 | 2011 |
| 1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig) JW Riess, RW Madison, K Tolba, AB Schrock, GR Oxnard, ES Sokol Annals of Oncology 33, S1032, 2022 | | 2022 |
| 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non … J Soria, LV Sequist, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... European Journal of Cancer, 199, 2014 | 14 | 2014 |
| 1290P Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion+ non-small cell lung cancer (NSCLC) O Gautschi, A Drilon, DSW Tan, GR Oxnard, C McCoach, K Goto, K Park, ... Annals of Oncology 31, S835, 2020 | | 2020 |
| 1301P Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): testing and treatment (Tx) patterns in the real … AM VanderWalde, J Lee, K Tolba, A Ward, M Cooper, RSP Huang, ... Annals of Oncology 32, S1006-S1007, 2021 | 1 | 2021 |
| 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of Thoracic Oncology 11 (4), S154, 2016 | 18 | 2016 |
| 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial MJ Ahn, J Yang, H Yu, H Saka, S Ramalingam, K Goto, SW Kim, L Yang, ... Journal of Thoracic Oncology 11 (4), S115, 2016 | 288 | 2016 |
| 1373P SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) U Swami, RP Graf, R Nussenzveig, V Fisher, H Tukachinsky, G Li, ... Annals of Oncology 33, S1170, 2022 | | 2022 |
| 1413TiP LIBRETTO-431: selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC) HHF Loong, K Goto, YY Elamin, B Solomon, FC Santini, V Soldatenkova, ... Annals of Oncology 31, S893, 2020 | 3 | 2020 |
| 1532P Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas K Ganjoo, R Madison, M Rosenzweig, G Oxnard, J Venstrom, A Ward, ... Annals of Oncology 32, S1116-S1117, 2021 | | 2021 |
| 2339P Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC FG dall'Olio, D Vasseur, A Mamann, CA Garcia, K Beshiri, A Marinello, ... Annals of Oncology 34, S1192-S1193, 2023 | | 2023 |
| 2396P Relationship of tumor fraction in circulating tumor DNA (ctDNA) with prognosis in patients with advanced urothelial cancer B Miron, G Li, A Clark, L Pasquina, RP Graf, G Oxnard Annals of Oncology 34, S1220, 2023 | | 2023 |
| 3 to 5 manuscripts S Acharya, P Adusumilli, M Ambrogi, A Anichini, S Arulananda, AM Baird, ... Journal of Thoracic Oncology 16 (6), 879-880, 0 | | |
| 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement A Varga, DR Camidge, LV Sequist, H Wakelee, SH Ou, JW Goldman, ... European Journal of Cancer 3 (51), S598, 2015 | 9 | 2015 |
| 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test S Gadgeel, JC Soria, JW Goldman, H Wakelee, DR Camidge, H Yu, ... European Journal of Cancer 3 (51), S628, 2015 | 2 | 2015 |
| 387P Phase Ib study of savolitinib±osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C T Hirashima, K Yoh, H Saka, T Kurata, Y Ohe, T Hida, A Mellemgaard, ... Annals of Oncology 31, S1393, 2020 | | 2020 |
| 457P Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations S Tejpar, H Tukachinsky, L Zhang, AB Schrock, B Decker, DC Pavlick, ... Annals of Oncology 32, S561, 2021 | 1 | 2021 |
| 5′ deletion on ALK break-apart FISH and risk of false positive results X Gao, LM Sholl, M Nishino, J Heng, PA Janne, GR Oxnard Cancer Research 75 (15_Supplement), 4250-4250, 2015 | | 2015 |
| 58 Examining elevated TMB and clinical benefit of 1L immune checkpoint inhibitor in advanced NSCLC D Carbone, J Sands, G Li, A Schrock, R Graf, L Zhang, K Murugesan, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
